Adlai Nortye (ANL) Operating Leases (2022 - 2025)

Adlai Nortye (ANL) reported Operating Leases of $1.1 million for Q4 2025, up 165.18% year-over-year from $425000.0 in Q4 2024, and up 338.52% on a QoQ basis from $257000.0 in Q2 2025.

Adlai Nortye (ANL) has 4 years of Operating Leases data on file, last reported at $1.1 million in Q4 2025.

  • Quarterly Operating Leases rose 165.18% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 165.18% YoY) and the FY2025 annual result came in at $1.1 million, up 165.18% from the prior year.
  • Operating Leases advanced to $1.1 million in Q4 2025 per ANL's latest filing, from $257000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.2 million in Q4 2022 and bottomed at $257000.0 in Q2 2025.
  • The 4-year median for Operating Leases is $553000.0 (2023), against an average of $691833.3.
  • The widest annual swing landed in 2023, when Operating Leases sank 62.06%; it then surged 165.18% in 2025.
  • Tracing ANL's Operating Leases over 4 years: stood at $1.2 million in 2022, then slumped by 62.06% to $469000.0 in 2023, then decreased by 9.38% to $425000.0 in 2024, then surged by 165.18% to $1.1 million in 2025.
  • Per Business Quant, the three latest ANL Operating Leases figures stand at $1.1 million (Q4 2025), $257000.0 (Q2 2025), and $425000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Adlai Nortye 23,840.00 -8.03 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.13 Mn
Jun 30, 2025 257,000.00
Dec 31, 2024 425,000.00
Jun 30, 2024 637,000.00
Dec 31, 2023 469,000.00
Dec 31, 2022 1.24 Mn